

Alnylam's franchise-extension plan bears fruit



[Madeleine Armstrong](#)

Alnylam already has one marketed amyloidosis therapy in the form of Onpattro. It could soon have another, more convenient option, following today's hit in the phase III [Helios A study](#) of vutrisiran. Alnylam is not saying much for now about Helios A, in the polyneuropathy subtype, except that this met its primary endpoint, mNIS+7 at nine months versus historical placebo data, as well as hitting both secondary measures. Vutrisiran also showed an improvement on a cardiac biomarker, NT-proBNP; more details will be needed to gauge the project's chances in the cardiomyopathy amyloidosis subtype, for which Onpattro is not approved but Pfizer's Vyndaqel and Vyndamax are. Full data from Helios A are expected at the American Academy of Neurology meeting in April; 18-month results, due later this year, should also include more details on cardiac endpoints. Alnylam's study of vutrisiran in cardiomyopathy, [Helios B](#), is not set to complete until 2024, but the group hopes that the Helios A data will be enough to help it penetrate the mixed amyloidosis phenotype "above and beyond" what Onpattro has managed. Alnylam, which is also working on a twice-yearly formulation of vutrisiran, saw its stock open up 8% this morning.

Top five amyloidosis therapies in 2026

Project	Company	Status	Delivery	2026e sales (\$m)
Vyndaqel/Vyndamax	Pfizer	Marketed*	Oral once daily	3,973
AG10 (acoramidis)	Bridgebio	Ph3	Oral twice daily	1,820
Vutrisiran	Alnylam	Ph3	SC every 3mths	1,290
Onpattro	Alnylam	Marketed**	IV every 3wks	1,015
Tegsedi	Ionis	Marketed**	SC once weekly	617

*Approved in US for cardiomyopathy subtype only; **Approved in US for polyneuropathy subtype only.
Source: EvaluatePharma.

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2023 Evaluate Ltd.